Riluzole extends survival in ALS by roughly 2 to 3 months on average, which translates to about a 9% increase in the chance of being alive at one year. That is a modest benefit by any measure, and it’s reasonable to question whether it’s worth taking. The honest answer is that most neurologists still recommend it, every major guideline endorses it, and most people with ALS choose to take it, but the decision is genuinely personal and depends on how you weigh a small survival gain against the side effects, blood monitoring, and cost.
What Riluzole Actually Does
ALS damages motor neurons, the nerve cells that control voluntary muscle movement. One factor in that damage is excess glutamate, a chemical messenger that becomes toxic to nerve cells in high concentrations. Riluzole works by reducing the amount of glutamate released at nerve terminals and by blocking some of its harmful effects on receiving cells. It essentially dials down a process called excitotoxicity, where overstimulated neurons are injured and die.
This mechanism slows the rate of motor neuron loss, but it does not stop or reverse it. In clinical trials, riluzole did not improve muscle strength or neurological function scores. People taking it still progressed. The benefit showed up only in survival data: patients on riluzole lived somewhat longer, or more precisely, went longer before needing a tracheostomy or dying.
How Much Extra Time It Provides
Across four placebo-controlled trials, riluzole at the standard dose (100 mg per day) was associated with a 17% relative reduction in the risk of death or tracheostomy at 18 months. In absolute terms, that works out to about 2 to 3 additional months of life. The benefit is real and statistically consistent, but it is small. No trial has shown riluzole dramatically changing the course of the disease.
It’s also important to understand what those extra months look like. Because riluzole does not slow functional decline in measurable ways, the additional survival time often comes at a stage when disability is already advanced. Some people find that deeply worthwhile. Others are less certain. Both perspectives are valid.
When Starting Matters
Evidence suggests riluzole works best when started earlier in the disease. The survival benefit seen in clinical trials was most apparent in patients who began treatment while they still had relatively preserved function. Starting riluzole in very advanced ALS, when respiratory function is already severely compromised, is less likely to produce a meaningful benefit. If you’re considering it, beginning sooner rather than later gives it the best chance of helping.
Side Effects and Monitoring
Most people tolerate riluzole reasonably well, but it does cause side effects. In clinical trials at the standard 100 mg daily dose, about 16% of patients experienced nausea (compared to 11% on placebo), 19% reported weakness or fatigue (compared to 12% on placebo), and about 4% had dizziness. These numbers mean that most of the nausea and fatigue people feel on riluzole would have happened anyway from the disease itself, but the drug adds a noticeable bump.
The more serious concern is liver toxicity. Riluzole can raise liver enzymes, and in rare cases it has caused acute liver failure. This means you’ll need blood tests monthly for the first three months, then every three months after that. If your liver enzymes climb too high, your neurologist will likely stop the medication. For most people, the monitoring is a minor inconvenience. For those already managing multiple appointments and tests, it adds to an already heavy schedule.
Cost and Accessibility
Riluzole has been available as a generic since its patent expired, which brought the price down dramatically. The retail price for a month’s supply (sixty 50 mg tablets) is listed around $730, but with discount coupons the out-of-pocket cost can drop to roughly $25 to $30 per month. Insurance typically covers it as well. Cost was once a significant barrier, but for most people in the U.S. today, it is manageable.
Combination With Other Treatments
Riluzole is often used alongside other ALS therapies. Preliminary research from a small retrospective study found that patients who consistently took a full combination of available treatments showed slower functional decline than those on partial treatment. Functional scores dropped about three times faster in the partial-treatment group. This is early evidence from a small sample, not a definitive trial, but it suggests riluzole may work best as part of a broader treatment approach rather than as a standalone medication.
Why Most People Still Take It
The UK’s National Institute for Health and Care Excellence recommends riluzole for ALS. The American Academy of Neurology supports its use. It remains the longest-standing approved treatment for the disease. The reason these bodies endorse a drug with a modest benefit is straightforward: ALS has very few treatment options, the side effect profile is manageable for most people, the cost is low, and even a few extra months of life hold real value for many patients and families.
That said, the decision is yours. A 2 to 3 month average survival benefit is a statistical summary across hundreds of patients. Some individuals may benefit more, some less. If the side effects are tolerable and the blood monitoring isn’t burdensome, most neurologists would say the trade-off favors taking it, especially early in the disease. If nausea or fatigue significantly worsens your quality of life, or if you’re at a stage where additional weeks feel less meaningful to you personally, choosing not to take it is a legitimate decision that your care team should support.